Buy Target – $56.00 or better Sell Target – TradersPro Sell Signal Endava plc provides technology services for clients in the consumer products, healthcare, logistics, and retail verticals in Europe, Latin America, and the United States. It offers strategy, creative and user experience, insights through data, mobile and Internet of Things, architecture, smart automation, software […]
Read MoreTrade Setup Buy Target $22.09 Sell Target $24.23 Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.
Read MoreTrade Setup Buy Target $102.10 Sell Target $113.75 Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung […]
Read MoreTrade Setup Buy Target $2.48 Sell Target $3.04 DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers […]
Read MoreTrade Setup Buy Target $2.05 Sell Target $2.28 Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases.
Read MoreAny pressure on these 3 managed care stocks is a buying opportunity according to one Cantor Fitzgerald analyst.
Read MoreTrade Setup Buy Target $10.16 Sell Target $11.04 Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib […]
Read MoreTrade Setup Buy Target $3.52 Sell Target $3.80 Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its […]
Read MoreBuy Target – $2.60 or better Sell Target – TradersPro Sell Signal Agile Therapeutics, Inc., a women’s healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.
Read MoreGoldman Sachs says all three Strong Buy stocks could see double-digit upside next year.
Read MorePlus, new details are emerging on the phase one trade deal between the U.S. and China, Boeing is officially halting production of the 737 Max, and Fiat Chrysler and Peugeot might be about to finalize a memorandum of understanding to merge.
Read MoreTrade Setup Buy Target $17.27 Sell Target $19.13 Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious […]
Read MoreAnalysts rate these 7 defensive picks Strong Buys.
Read MoreTrade Setup Buy Target $4.05 Sell Target $4.79 Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Read MoreTrade Setup Buy Target $17.29 Sell Target $19.46 MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic […]
Read More